Lung Cancer Diagnostics

Global Market Trajectory & Analytics

MCP16923

EXECUTIVE ENGAGEMENTS

OUTREACH

3123
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

562
Interactions with Platform & by Email

PARTICIPANTS

94
Unique # Participated

VALIDATIONS

42
Responses Validated*

COMPETITORS

48
Responses Validated*

BRANDS

201
Responses Validated*
* Login for a full stack data experience

DATE

APR 2021

TABLES

306

PAGES

605

EDITION

8

PRICE

USD $5450


  

HIGHLIGHTS

The global market for Lung Cancer Diagnostics is projected to reach US$3.2 billion by 2025, driven by rising incidence and growing economic burden of lung cancer in terms of survival rates and medical expenditure. Rising environmental pollution is taking its toll on the health of the population. Among the many factors attributed to the epidemic spread of cancer is the rising air pollution as evidenced by unchecked presence of particulate matter (PM10 and PM2.5) in outdoor and indoor air. Increase in the cacogenic load in the environment is catalyzing the prevalence of all types of cancers. Exposure to particulate matter (PM2.5) in the air as a result of deteriorating air quality in global cities is a key reason amplifying the incidence and prevalence of lung cancer. Thousands of cities today have air pollution significantly higher than the safe levels established by WHO, exposing billions of people around the world to dangerous air. Over 8.5 million deaths occur each year due to exposure to fine particles in polluted air, with lung cancer leading the mortality rate.

Against the backdrop of the emerging picture of disease severity, there is growing focus shed on early detection, diagnosis and supportive treatment. Given that any cancer when detected at an early stage before it has spread has a higher likelihood of being successfully treated, there is strong focus shed on lung cancer screening. Screening provides new hope for early detection and more successful treatment of lung cancer. As compared to other cancers, survival rates associated with lung cancer is low and the disease is often identified only at advanced stages since symptoms closely mimic those associated with infections, emphysema, COPD and smoking thereby leading to misdiagnosis. Currently gaining significance is a low-dose CAT scan (LDCT) with research studies proving the diagnostic technique to be effective in identifying abnormal lesions in the lungs in high risk patients. Also a growth driver is the expanding base of high risk population which includes aging people in the 60+ age group, growing number of smokers, rise in COPD which is a major risk factor for cancer and premature lung aging.

A key sector of the market poised to witness above average growth is the emerging field of liquid biopsies. Until recently, testing for mutations was carried out only by tissue-biopsy-based testing which is ridden with challenges and clinical inefficiency. Tissue biopsies are effective in confirming a diagnosis and identifying corresponding molecular abnormalities. However, the test does not offer the in-depth understanding of the tumor which is required for timely and effective treatment. Liquid biopsy, on the other hand, enhances the effectiveness of the treatment of NSCLC, with the ability to circumvent all the biological limitations of tissue biopsy. A key of benefit of liquid biopsies will however be a reduction in the number of unrequired and unnecessary tissue biopsies. This is a significant advantage especially in the current era of value based care which aims to reduce healthcare wastages. The benefit in healthcare cost savings can be put into perspective by the fact that in the United States in the breast cancer sector alone over 1.5 million breast tissue biopsies are performed annually with only 25% of these tests resulting in a confirmatory cancer diagnosis. Liquid biopsies given their ability provide greater diagnostic insights can help close the wastages involved in cancer diagnosis. The United States and Europe represent large markets worldwide with a combined share of 49.3% of the global market. China ranks as the fastest growing market with a CAGR of 11.4% over the analysis period supported by rising incidence of lung cancer as a result of diversity in lifestyles and socioeconomic development including occupational factors.

SELECT PLAYERS

Abbott Diagnostics - Core Laboratory; Dr Lal PathLabs; F. Hoffmann-La Roche AG; Illumina Inc.; Myriad Genetics Inc.; NanoString Technologies; NeoGenomics Laboratories Inc.; PlexBio Co., Ltd.; QIAGEN GmbH; Quest Diagnostics; Thermo Fisher Scientific Inc.

SEGMENTS

» Test (Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy, and Other Tests) » Type (Non-Small-Cell Lung Cancer (NSCLC), and Small-Cell Lung Cancer (SCLC) » and End-Use (Hospital Laboratories, Cancer Research Institutes, and Other End-Uses)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » Spain » Russia » and Rest of Europe » Asia-Pacific » Australia » India » South Korea » and Rest of Asia-Pacific » Latin America » Argentina » Brazil » Mexico » and Rest of Latin America » Middle East » Iran » Israel » Saudi Arabia » United Arab Emirates » and Rest of Middle East » and Africa

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Early Detection of Lung Cancer Takes Precedence, Driving the Demand for Lung Cancer Diagnostics
Non-small Cell Lung Cancer - The More Prominent of the Two Lung Cancer Types
Imaging Tests Segment Dominates the Market, Molecular Tests Category to Witness High Growth
US Leads the Lung Cancer Diagnostics Market, Asia-Pacific to Witness Fastest Growth
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
Agilent Technologies Inc. (USA)
F. Hoffmann-La Roche Ltd. (Switzerland)
Illumina, Inc. (USA)
NeoGenomics Laboratories, Inc. (USA)
QIAGEN N.V. (The Netherlands)
Thermo Fisher Scientific, Inc. (USA)
Veracyte (USA)
3. MARKET TRENDS & DRIVERS
Increasing Prevalence and Incidence of Lung Cancer to Push the Demand for Early Diagnoses
Age-Standardized Lung Cancer Rates for Select Countries
Age-Standardized Lung Cancer Rates in Men for Select Countries
Age Standardized Lung Cancer Rates in Women for Select Countries
Lung Cancer-Specific Biomarkers to Spur Market Growth
Select Lung Cancer Biomarkers
New Potential Biomarker for Early Stage Lung Cancer Identified in a Recent NCI Study (2019)
Advancements and Research Initiatives in Lung Cancer Diagnostics Space
EFIRM Test for Detection of Lung Cancer-related EGFR Mutations in NSCLC Patients
A Glance at Select Recent Launches of Lung Cancer Diagnostic Tests
New Product Launches/Approvals in the Lung Cancer Diagnostics
Recent Approvals
Liquid Biopsies Grow in Value as a Diagnostic Tool Supporting Therapy Decisions in NSCLCs
Effervescent Rate of New Innovations & Product Development Will Make Liquid Biopsy a Readily Available Option for Patients in the Coming Years
High Cigarette Consumption/Rise in Prevalence of Smoking Increases the Incidence of Lung Cancer
Cigarette Consumption Per Year Per Person Across Select Countries: 2016
Top 15 Countries with the Highest Smoking Rates: 2015
Increasing Number of Awareness Programs for Lung Cancer and Symptoms
Growing Availability of Government/Private Funding for R&D to Develop Lung Cancer Diagnostics
Table: National Cancer Institute Research Funding for Lung Cancer in US$ Million for the Years 2014 through 2017
Aging Demographics & Unhealthy Lifestyles Raise the Risk of Cancer
Cancer Prone Sites based on Age
Table: Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
4. GLOBAL MARKET PERSPECTIVE
World Current & Future Analysis for Lung Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Lung Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Lung Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027
World Current & Future Analysis for Imaging Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Imaging Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Imaging Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
World Current & Future Analysis for Sputum Cytology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Sputum Cytology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Sputum Cytology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
World Current & Future Analysis for Molecular Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Molecular Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Molecular Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
World Current & Future Analysis for Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
World Current & Future Analysis for Other Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Other Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Other Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
World Current & Future Analysis for Non-Small-Cell Lung Cancer (NSCLC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Non-Small-Cell Lung Cancer (NSCLC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Non-Small-Cell Lung Cancer (NSCLC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
World Current & Future Analysis for Small-Cell Lung Cancer (SCLC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Small-Cell Lung Cancer (SCLC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Small-Cell Lung Cancer (SCLC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
World Current & Future Analysis for Hospital Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Hospital Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Hospital Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
World Current & Future Analysis for Cancer Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Cancer Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Cancer Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
World Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
UNITED STATES
Lung Cancer Stats
US Lung and Bronchus Cancer New Cases by Gender: 2019E
US Lung and Bronchus Cancer Deaths by Gender: 2019E
Incidence Rates* for Lung and Bronchus Cancer by Gender, 2011-2015
Death Rates* for Lung and Bronchus Cancer by Gender in the US, 2012-2016
Incidence Rates for Lung and Bronchus Cancer by Race/Ethnicity, 2011-2015
Reimbursement and Insurance Coverage for Lung Cancer Screening in the US
CY 2019 Medicare Physician Fee Payment Levels for Low Dose CT Scan (LDCT) Screening
CY 2019 Hospital Outpatient Prospective Payment System (HOPPS) Payment Levels for Low Dose CT Scan (LDCT) Screening
Oncimmune’s EarlyCDT Lung to be commercialized in the US by Biodesix (2019)
Market Analytics
USA Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
USA Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
USA Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
USA Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
USA Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
USA Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
CANADA
Canada Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
Canada Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
Canada Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
JAPAN
Japan Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
Japan Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
Japan Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
CHINA
China Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
China Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
China Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
China Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
China Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
China Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
EUROPE
Europe Current & Future Analysis for Lung Cancer Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Europe Historic Review for Lung Cancer Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Lung Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
Europe Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
Europe Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
Europe Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
FRANCE
France Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
France Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
France Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
France Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
France Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
France Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
GERMANY
Germany Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
Germany Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
Germany Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
ITALY
Italy Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
Italy Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
Italy Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
UNITED KINGDOM
TABLE: UK Age-standardised Rate (per 100,00) of Lung Cancer Cases by Gender: 1980-2035P
UK Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
UK Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
UK Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
UK Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
UK Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
UK Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
SPAIN
Spain Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Spain Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Spain 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
Spain Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Spain Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Spain 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
Spain Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Spain Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Spain 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
RUSSIA
Russia Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Russia Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Russia 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
Russia Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Russia Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Russia 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
Russia Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Russia Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Russia 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
REST OF EUROPE
Rest of Europe Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
Rest of Europe Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
Rest of Europe Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
ASIA-PACIFIC
Asia-Pacific Current & Future Analysis for Lung Cancer Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Lung Cancer Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Lung Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027
Asia-Pacific Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
Asia-Pacific Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
Asia-Pacific Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
AUSTRALIA
Australia Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Australia Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Australia 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
Australia Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Australia Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Australia 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
Australia Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Australia Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Australia 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
INDIA
Rise in Incidence of Lung Cancer in India
Table: New Cancer Cases in India by Site: 2018
India Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
India Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
India 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
India Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
India Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
India 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
India Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
India Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
India 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
SOUTH KOREA
South Korea Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
South Korea Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
South Korea 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
South Korea Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
South Korea Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
South Korea 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
South Korea Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
South Korea Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
South Korea 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
REST OF ASIA-PACIFIC
Rest of Asia-Pacific Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Asia-Pacific Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Asia-Pacific 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
Rest of Asia-Pacific Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Asia-Pacific Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Asia-Pacific 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
Rest of Asia-Pacific Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Asia-Pacific Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Asia-Pacific 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
LATIN AMERICA
Latin America Current & Future Analysis for Lung Cancer Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Latin America Historic Review for Lung Cancer Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Latin America 15-Year Perspective for Lung Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027
Latin America Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Latin America Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Latin America 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
Latin America Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Latin America Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Latin America 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
Latin America Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Latin America Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Latin America 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
ARGENTINA
Argentina Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Argentina Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Argentina 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
Argentina Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Argentina Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Argentina 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
Argentina Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Argentina Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Argentina 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
BRAZIL
Brazil Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Brazil Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Brazil 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
Brazil Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Brazil Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Brazil 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
Brazil Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Brazil Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Brazil 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
MEXICO
Mexico Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Mexico Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Mexico 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
Mexico Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Mexico Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Mexico 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
Mexico Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Mexico Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Mexico 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
REST OF LATIN AMERICA
Rest of Latin America Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Latin America Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Latin America 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
Rest of Latin America Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Latin America Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Latin America 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
Rest of Latin America Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Latin America Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Latin America 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
MIDDLE EAST
Middle East Current & Future Analysis for Lung Cancer Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Middle East Historic Review for Lung Cancer Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Middle East 15-Year Perspective for Lung Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027
Middle East Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Middle East Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Middle East 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
Middle East Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Middle East Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Middle East 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
Middle East Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Middle East Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Middle East 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
IRAN
Iran Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Iran Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Iran 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
Iran Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Iran Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Iran 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
Iran Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Iran Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Iran 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
ISRAEL
Israel Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Israel Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Israel 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
Israel Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Israel Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Israel 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
Israel Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Israel Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Israel 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
SAUDI ARABIA
Saudi Arabia Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Saudi Arabia Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Saudi Arabia 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
Saudi Arabia Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Saudi Arabia Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Saudi Arabia 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
Saudi Arabia Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Saudi Arabia Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Saudi Arabia 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
UNITED ARAB EMIRATES
UAE Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
UAE Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
UAE 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
UAE Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
UAE Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
UAE 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
UAE Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
UAE Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
UAE 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
REST OF MIDDLE EAST
Rest of Middle East Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Middle East Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Middle East 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
Rest of Middle East Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Middle East Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Middle East 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
Rest of Middle East Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Middle East Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Middle East 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
AFRICA
Africa Current & Future Analysis for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Africa Historic Review for Lung Cancer Diagnostics by Test - Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Africa 15-Year Perspective for Lung Cancer Diagnostics by Test - Percentage Breakdown of Value Sales for Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy and Other Tests for the Years 2012, 2020 & 2027
Africa Current & Future Analysis for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Africa Historic Review for Lung Cancer Diagnostics by Type - Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Africa 15-Year Perspective for Lung Cancer Diagnostics by Type - Percentage Breakdown of Value Sales for Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC) for the Years 2012, 2020 & 2027
Africa Current & Future Analysis for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Africa Historic Review for Lung Cancer Diagnostics by End-Use - Hospital Laboratories, Cancer Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Africa 15-Year Perspective for Lung Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital Laboratories, Cancer Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
Total Companies Profiled: 48 (including Divisions/Subsidiaries - 48)

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com